Product category: Equipment for treatment with gases, Respiration equipment, Oxygen equipment
The operational safety of the unit is only assured when used for the purpose it is intended for, as specified in the instructions for use.
The ReOxy device must only be used according to the medical indication and only in accordance with the doctor's prescription by following instructions for use.
The intended use also includes the compliance with the assembly instructions, as well as the notes on cleaning and maintenance of the ReOxy device.
Any other use of the unit beyond these limits is prohibited and is not considered as unintended use! Claims of any kind against the manufacturer and/or his authorized representatives resulting from damage caused by unintended use of the unit are excluded. The operator is solely liable for any damage resulting from unintended use.
Ai Mediq Group was founded in 2003 by a group of scientists in search of methods of preventive and preventativemedicine. The medical community has expressed a critical need for a device to provide interval hypoxia therapy for treating cardiovascular, neurological and metabolic diseases. A new treatment method has been developed, relevant patents registered and preclinical trials started.
In 2009, the company established its headquarters in Luxembourg and was officially incorporated as Ai Mediq S.A.
Ai Mediq S.A. began to develop a prototype for the new treatment method focused on screening analysis and biofeedback (SRT-Technology). This technology automatically adjusts procedure parameters in response to alterations in SpO2 and pulse oximeter heart rate readouts during the whole procedure.
In 2012 Ai Mediq S.A. presented ReOxy breathing therapy device to an international audience during World Cardiological Congress 2012 in Dubai, UAE.
The companys product offering continues to evolve and expand and is permanently focused on areas that are vital for the improvement of patient care.